Search results
A study in Nature in July 2024[1], raised the idea that blocking the interleukin 11 (IL-11) by using an IL-11 antibody could be a proposition for a healthy increase in lifespan, based on the outcomes in their experimental mouse subjects.
9 maj 2023 · The company’s lead candidate, LASN01, is a first-in-class monoclonal antibody targeting IL-11 receptor (IL-11R). IL-11 is a central mediator of fibrosis and blocking its activity has the potential to offer novel modality for treatment of TED and other fibrotic diseases.
IL-11 plays a key role in fibrosis across multiple organs and pre-clinical studies have shown that anti-IL-11 treatment has the potential to stop – and even reverse fibrosis – in different fibrotic diseases. Boehringer Ingelheim joined forces with Enleofen, a leader in IL-11 biology, in 2020.
18 lip 2024 · Blocking IL-11 signaling extends lifespan and healthspan in mice, reducing age-related metabolic decline, frailty, and cancer incidence.
9 sty 2020 · In return for rights to the IL-11 assets, Boehringer has put together a package that is worth up to $1 billion (€900 million) per product in upfront fees and milestones.
28 wrz 2022 · The company’s lead candidate is LASN01, a best-in-class monoclonal antibody targeting IL-11 receptor (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis and blocking its activity has the potential to be safer than, and additive to, other anti-fibrotic therapeutic approaches.
17 lip 2024 · IL-11 is identified as a key regulator of ERK–AMPK–mTORC1 signalling, metabolism, inflammation and age-related disease and lifespan in mouse and human.
